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The purpose of the study is to develop an ultra performance liquid chromatography-
tandem mass spectrometry (UPLCeMS/MS) to determinate the concentration of azilsar-
tan in the dog plasma. After precipitated by methanol, the plasma sample containing
azilsartan and diazepam (internal standard, IS) was determined by UPLCeMS/MS. The
mobile phase consisted of acetonitrile-water was pumped at a flow rate of 0.3 ml/min in
gradient elution. Kinetex 2.6 m XB-C18 column (50  2.1 mm, 100 Å; Phenomenex, USA)
were used for LC separations. The column temperature was 30 C and the injection volume
was 5 ml. The electrospray ionization (ESI) and multiple reaction monitoring (MRM) were
applied at the transitions of m/z 457 / 279 (azilsartan) and m/z 285 / 193 (diazepam),
respectively. The developed method was identified a good linearity over a concentration
range of 2.5e5000 ng/ml. The lower limit of quantitation (LLOQ) was 2.5 ng/ml. The intra-
day and inter-day precision (relative standard deviation, RSD%) were less than 10% and
accuracy (relative error, RE %) was less than 5% at three quality control levels. The
extraction recovery of azilsartan at three quality control levels were 82.41 ± 0.68%,
98.66 ± 11.00%, 102.43 ± 0.82%. And the recovery for IS (100 ng/ml) was 91.75 ± 0.54%. A
validated UPLCeMS/MSmethod was firstly developed for the quantification of azilsartan in
dog plasma and it was applied to the pharmacokinetics study.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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Azilsartan, a new generation of angiotensin II receptor
blocker (ARB), was successfully developed by Takeda in 2012
and the trade name is Azilva®. It is themain activemetabolite
of azilsartan medoxomil [1] which was approved as an anti-
hypertention drug by US Food and Drug Administration
(FDA) in 2011. Azilsartan selectively binds to the angiotensin
II AT 1 receptor to inhibit the actions of angiotension II and
results in lowering blood pressure (BP) [2]. According to the
drug label and literatures, azilsartan is principally absorbed
in the upper parts of small intestine, and the best absorption
sides are duodenum and jejunum [3e5]. The volume of dis-
tribution of azilsartan is approximately 16 L and it is highly
bound to human plasma proteins [6]. Azilsartan is metabo-
lized to two main metabolites by cytochrome P450 2C9
(CYP2C9). And the major pathways for the elimination of
azilsartan are feces and urine [5,7]. The recommended dose
and maximum dose in adults are 20 mg and 40 mg taken
orally per day. Compared with olmesartan and valsartan at
maximal approved doses, azilsartan has superior efficacy at
its maximal dose [8] and no significant increases in adverse
events (cardiovascular, cerebrovascular and renal events) are
observed [9,10]. Azilsartan shows sustaining reduction in BP
even after 24 h administrated to rat and dog [11]. What's
more, azilsartan is well tolerated in patients with hyperten-
sion [12].
At present, most literatures about azilsartan or azilsartan
medoxomil focus on its antihypertensive efficacy and safety
[13e16]. For future pharmacokinetics study, the method to
quantify the concentration of azilsartan in plasma is needed.
However, there is no reported UPLCeMS/MS method for
determination of azilsartan in plasma.
In this study, methanol was added to the plasma sample to
precipitate the protein, and the analyte and endogenous
components were separated by the gradient elution. The
UPLCeMS/MSmethodwith simple procedure, high-sensitivity
(LLOQ ¼ 2.5 ng/ml) and short analytical time (3.5 min per
sample) was first developed to assay the azilsartan in beagle
dog plasma and was successfully applied to the pharmacoki-
netic study.2. Materials and methods
2.1. Materials
Azilsartan (99.8%) was kindly provided by Weigao Pharm.
Co. Ltd. (Shandong, China). Diazepam (internal standard,
IS > 99.0% purity) was purchased from Baoyuan Pharm. Co.
Ltd. (Shanxi, China). HPLC-grade acetonitrile and methanol
were obtained from Fisher Scientific (Pittsburgh, PA, USA).
HPLC-grade Formic acid was purchased from Dikma (Rich-
mond Hill, NY, USA). Double distilled water was used
throughout the study. The azilsartan tablets (Azilva®) were
purchased from Takeda Pharm. Co. Ltd. (Tokyo, Japan). The
azilsartan test tablets were prepared in the laboratory.2.2. Instrumentation
The UPLCeMS/MS system consisted of a Waters ACQUITY
UPLC system and a TandemQuadrupole (TQ) Detector with an
electrospray ionization (ESI) interface (Waters Corp., USA). All
data were processed by MassLynx 4.1 software with the
QuanLynx program (Waters Corp., USA).2.3. UPLC/MS/MS conditions
The analytical column used was Kinetex 2.6 m XB-C18 column
(50  2.1 mm, 100 Å; Phenomenex, USA). The column was
maintained at 30 C. The mobile phase was composed of sol-
vent A (acetonitrile with 0.2% Formic acid) and solvent B (0.2%
Formic acid). The gradient program startedwith 40% solvent A
for 1.0min. The percentage of solvent Awas increased linearly
to 80% from 1.0 min to 2.5 min and was decreased linearly to
40% from 2.51 min to 3.0 min. Then the percentage of solvent
A maintained 40% from 3.0 min to 3.5 min and the gradient
programwas completed. The flowwas always at 0.3ml/min in
the gradient program.
For MS detection, the electrospray ionization source was
operated in a positive mode (ESIþ). Cone voltage and collision
energy were 20 V, 14 V for azilsartan and 30 V, 25 V for diaz-
epam (internal standard, IS), respectively. The temperature
and gas flow of de-solvent were 350 C and 650 L/h. To analyze
the drugs in plasma, multiple reaction monitoring (MRM) was
used at the transitions ofm/z 457/ 279 for azilsartan andm/z
285/ 193 for diazepam, respectively, with a scan time of 0.2 s.2.4. Preparation of standard and quality control (QC)
samples
The stock solutions of azilsartan and IS were prepared in
methanol at 100 mg/ml and 1 mg/ml, respectively. Then they
were diluted to 10 mg/ml for azilsartan and 100 ng/ml for IS
with methanol-water (80:20, v/v) to obtain standard solutions.
The standard solutions of azilsartan were used for preparing
the calibration curve and QC samples. The calibration curve
was prepared by spiking 200 ml of blank plasma with 200 ml of
appropriate azilsartan standard solution and 200 ml IS stan-
dard solution. Then 400 ml of methanol was added to the
sample. Finally, the calibration curve was prepared at the
concentration of 2.5, 5, 10, 20, 50, 200, 500, 1000, 4000 and
5000 ng/ml. And the QC samples for azilsartan at the con-
centration of 5, 200, 4000 ng/ml was prepared as the same
process.2.5. Plasma sample preparation
200 ml of IS standard solution (100 ng/ml) and 200 ml of
methanol-water (80: 20, v/v) were added to 200 ml plasma. The
mixture was vortex-mixed for 3 min. 400 ml of methanol was
added to the sample to precipitate the protein and then the
mixture was vortex-mixed for 3 min again. After that, the
sample was centrifuged at 13,000 rpm for 10 min. At the end,
5 ml supernatant was injected into the UPLCeMS/MS system.
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2.6.1. Selectivity
The selectivity of the method was to distinguish and quantify
the analyte in the plasma samples. To confirm the selectivity
of the method, the chromatograms of six different batches of
blank plasma and the corresponding spiked samples were
compared.
2.6.2. Calibration curve and lower limit of quantitation
The calibration curve was determined by plotting the peak
area ratio (A, area of analyte/area of IS) versus the concen-
tration using weighted (1/C2) least square linear regression.
The lower limit of quantitation (LLOQ), 10 times greater than
the ratio of signal-to-noise, was determined.Fig. 1 e Mass spectra of azilsartan (A) and IS2.6.3. Precision and accuracy
The precision and accuracy expressed as relative standard
deviation (RSD) and relative error (RE), respectively, were
calculate by analyzing the QC samples at low (5 ng/ml), me-
dium (200 ng/ml) and high (4000 ng/ml) concentration on
three validation days.
2.6.4. Extraction recovery and matrix effect
The extraction recovery of azilsartan was assessed by
comparing the peak areas of the extracted QC samples with
those of the samples which mixed corresponding standard
solutions with the extracted blank plasma. The matrix effect
of azilsartan was determined by comparing the peak areas of
the analyte at low, medium and high concentration in the
extracted blank plasma with those of the corresponding(B) in full scan positive ionization mode.
Fig. 2 e Representative MRM chromatograms of azilsartan and diazepam (IS) in dog plasma samples: (A) blank plasma, (B)
blank plasma spiked with azilsartan (2.5 ng/ml) and diazepam (100 ng/ml), (C) plasma from a dog after single oral
administration of 20 mg azilsartan.
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epam (IS) were also determined.
2.6.5. Stability
The stability test was regard as an important part of the
method validation. The stability of azilsartan in the plasma
samples was evaluated under various conditions, including at
ambient temperature (25 C) for 12 h, post-processed for 12 h,
freezeethaw cycles for 3 times and long-term stability (20 C
for 20 days). All stability tests were analyzed by QC samples
(n ¼ 3) at low, medium and high concentration.
2.7. Pharmacokinetics application
The above-mentioned validated method was successfully
used to analyze plasma samples for a pharmacokinetic study
of azilsartan. The animal protocols in the study were
approved by the Shenyang Pharmaceutical University Animal
Care and Use Committee.
Six healthy beagle dogs (weight 10e12 kg) were segmented
into two groups randomly, and study in a crossover experi-
mental design. The washout period is a week. Dogs were
fasted for a night before the experiment, but have free access
to water. Each group was administrated orally with commer-
cial tablets (Azilva®, Reference) and self-made tablets (Test),
respectively. The dosage of administration is 20 mg.
Blood samples (2 ml) were collected in heparinized tubes
from forearm vein of the dog before drug administration and
at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 14 and 24 h post-
dosing. Then the plasma was separated by centrifugation at
3000 rpm for 10min and kept in the refrigerator at20 C until
analysis.
The main pharmacokinetic parameters were calculated by
the DAS 2.0 software (Mathematical Pharmacology Profes-
sional Committee of China, Shanghai, China).3. Results and discussion
3.1. Optimization of LC-MS/MS condition
Both azilsartan and diazepam (IS) are polar compounds. The
electrospray ionization source was set to a positive mode
(ESIþ) in order to offer higher signal intensity for them. The
cone voltage and collision energy of azilsartan and IS were
developed for the best response of the parent and daughter
ions. The protonated molecular ions [M þ H]þ with greatest
response in the daughter-ion mass spectrumwerem/z 279 for
azilsartan andm/z 193 for IS as shown in Fig. 1. Variousmobile
phases were attempted in this study. For the sake of obtainingTable 1 e Precision and accuracy for the determination of azils
n ¼ 6; inter-day, n ¼ 18; mean ± SD).
Added (ng/ml) Intra-day
Found (ng/ml) RSD (%) R
5 4.75 ± 0.19 3.9
200 191.05 ± 6.93 3.6
4000 4144.72 ± 7.60 1.7good peak shapes with short retention time, the mobile phase
consisted of 0.2% formic acid and acetonitrilewith 0.2% formic
acid. The gradient elution in this method was developed
to ensure that the assay was not interfered by endogenous
substances.3.2. Method validation
3.2.1. Specificity
The specificity of the analytical method was evaluated by
comparing the representative MRM chromatograms of (A)
blank plasma, (B) blank plasma spiked with azilsartan (at the
concentration of LLOQ) and IS (100 ng/ml), (C) plasma from a
dog after single oral administration of 20 mg azilsartan in
Fig. 2. And no endogenous interference for azilsartan or IS was
observed. The analytical time was 3.50 min for each sample.
The retention times of azilsartan and IS were 1.99 min and
2.11 min, respectively.
3.2.2. Linearity and sensitivity
The calibration curves over the concentration range of
2.5e5000 ng/ml showed a good linearity. The typical regres-
sion equation was shown as the following equation:
A ¼ 0.130049C þ 0.110229 (correlation coefficient, r ¼ 0.9971),
where A stands for the ratio of the peak area of analyte to the
peak area of IS and C stands for the concentration of azilsartan
in the plasma. All correlation coefficients exceeded 0.9950 on
three validation days.
LLOQ was determined as 2.5 ng/ml and the precision (RSD
%) and accuracy (RE %) values were 6.75% and 10.80%,
respectively, within the acceptable range of ±20%.
3.2.3. Precision and accuracy
The intra- and inter-day precision and accuracy for the
determination of azilsartan were listed in Table 1. From the
results, it indicated that the intra-day precision and accuracy
were all less than 6% while the inter-day precision and accu-
racy were all less than 9%. All the results were within the
acceptable range of ±15%.
3.2.4. Extraction recovery and matrix effect
The extraction recoveries for azilsartan at low (5 ng/ml), me-
dium (200 ng/ml) and high (4000 ng/ml) concentrations were
82.41 ± 0.68%, 98.66 ± 11.00%, 102.43 ± 0.82%. The recovery for
IS (100 ng/ml) was 91.75 ± 0.54% (n ¼ 6).
The matrix effects for azilsartan at three concentration
levels (5, 200 and 4000 ng/ml) were 105.43 ± 8.16, 99.41 ± 3.43,
and 104.37 ± 1.99%, respectively. The matrix effects of IS was
93.66 ± 3.76%. All the ratios of matrix effects for azilsartan and
IS were within the acceptable range of ±15%. The resultsartan in dog plasma samples by UPLCeMS/MS (intra-day,
Inter-day
E (%) Found (ng/ml) RSD (%) RE (%)
5.0 4.94 ± 0.44 8.9 1.2
4.5 203.37 ± 13.03 6.4 1.7
3.6 3994.24 ± 119.04 3.0 0.1
Table 2 e Stability of azilsartan in beagle dog plasma









Ambient (25 C) for 12 h 5 4.67 ± 0.40 8.7 6.7
200 205.07 ± 5.06 2.5 2.5
4000 3619.10 ± 21.80 0.6 9.5
Post preparation for 12 h 5 4.43 ± 0.51 11.6 11.3
200 199.80 ± 5.39 2.7 0.1
4000 3620.73 ± 40.43 1.1 9.5
Three freezeethaw cycles 5 4.47 ± 0.38 8.5 10.7
200 203.70 ± 5.14 2.5 1.8
4000 3646.47 ± 44.62 1.2 8.8
Long-term stability
(20 C for 20 days)
5 4.53 ± 0.35 7.7 9.3
200 203.77 ± 1.40 0.7 1.9
4000 3618.20 ± 40.85 1.1 9.4
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were discovered in this study.
3.2.5. Stability
The stability test was performed by analyzing replicates (n¼ 3)
of QC samples at low,medium and high concentrations under
different conditions. All the data of the stability test were
shown in Table 2. It suggested that the azilsartan showed a




of pharmacokinetic behaviors of azilsartan in beagle dogs. The
mean plasma concentrationetime curves for azilsartan mar-
keted tablets (Reference) and self-made tablets (Test) after oral
administration to six healthy beagle dogs are shown in Fig. 3.
The Tmax and Cmax were obtained directly from the curves. It
was clearly indicated that Cmax were 955.33 ± 272.39 ng/ml for
Referece and 939.68 ± 335.41 ng/ml for Test, respectively, whileFig. 3 e Mean plasma concentrationetime curves for
azilsartan marketed tablets (Reference), self-made tablets
(Test) after oral administration to six healthy beagle dogs
(data were mean ± SE, n ¼ 6).theTmaxwere 0.75± 0.09hand1.50± 0.28h.AUC0e24h values for
ReferenceandtheTeswere foundtobe3387.36±866.96ng/ml$h
and 3121.05 ± 770.54 ng/ml$h, respectively. The data were
shown as mean ± standard error (n ¼ 6). The relative bioavail-
ability of Test compared with Reference was 108.53%.4. Conclusion
In this study, a rapid, selective and sensitive UPLCeMS/MS
method was developed for the determination of azilsartan in
beagle dog plasma. The precision, extraction recovery, matrix
effect and stability of this method have been validated. It has
been successfully used for the pharmacokinetic study of
azilsartan in beagle dog plasma for the first time.r e f e r e n c e s
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